Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATROPIN: Sacituzumab govitecan + atropine in advanced breast cancer
2025-524109-33-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) and breast cancer, sponsored by MEDSIR. Primary endpoint: Incidence of grade ≥2 diarrhea during first two treatment cycles. Planned start Mar 2026; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2025-524109-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524109-33-00.